- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01646203
A Study of IMC-TR1 in Participants With Advanced Solid Tumors
Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Texas
-
Houston, Texas, United States, 77030
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
San Antonio, Texas, United States, 78229
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Part A and Part B: Participants must be appropriate candidates for experimental therapy, with a solid tumor that has failed standard therapy or for which no standard therapy is available, and evidence of progressive disease
- Part A only: Participants must have histological or cytological evidence of a solid tumor which is advanced and/or metastatic
- Part B only: Participants who have failed first-line therapy/standard of care and have histological or cytological evidence of a cancer type for which evidence of activity was observed during Part A or for which preclinical evidence of potential activity has been observed
Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)
- Part A only: Participants may have measurable or nonmeasurable disease
- Part B: Participants must have measurable disease
- Have adequate organ function including: Hematologic, Hepatic, Albumin, Coagulation and Renal function
- Have a performance status of ≤ 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- Have discontinued previous treatments for cancer and recovered from the acute effects of therapy
- Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug
- Females with child bearing potential must have had a negative serum pregnancy test and must not be breastfeeding
- Have an estimated life expectancy that is > 3 months
Exclusion Criteria:
Have clinically significant cardiac disease, including:
- Myocardial infarction within 6 months prior to study entry, unstable angina pectoris, congestive heart failure, or uncontrolled hypertension
- Major electrocardiogram (ECG) abnormalities
- Major abnormalities documented by echocardiography with Doppler
- Have known predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress
- Have Corrected QT Interval (QTc interval) of > 500 msec on screening ECG
- Have other known serious pre-existing medical conditions
- Have received prior investigational therapy targeting Transforming growth factor beta (TGFβ) or its receptors
- Have a known sensitivity to monoclonal antibodies or other therapeutic proteins, to agents of similar biologic composition as IMC-TR1
- Have a high risk of gastrointestinal bleeding, active inflammatory bowel disease, or chronic steroid use
- Are currently using or has received a systemic thrombolytic agent within 28 days prior to enrollment
Are receiving:
- full-dose warfarin
- intravenous heparin or low-molecular-weight heparin
- chronic daily treatment with aspirin at a dose greater than 325 mg per day or nonsteroidal anti-inflammatory medications known to inhibit platelet function
- Have evidence of retinal disease or are a monocular participant
- Have received a solid organ transplant, bone marrow transplant or stem cell transplant
- Have symptomatic central nervous system (CNS) malignancy or untreated metastasis
- Have acute or chronic leukemia
- Have a known active fungal, bacterial, and/or viral infection including human immunodeficiency virus or viral hepatitis requiring treatment
- Has a positive fecal occult blood test within 14 days prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMC-TR1
Part A - Dose Escalation: Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles Part B - Disease Specific Cohort Expansion: Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose. |
Administered intravenously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose-Limiting Toxicities (DLTs)
Time Frame: First Dose Up to 6 Weeks
|
A DLT was defined as an AE occurring during Cycle 1(first 6 weeks of treatment) that was considered at least possibly related to study drug, was considered dose-dependent, and fulfilled a criteria selected (using the National Cancer Institute Common Terminology Criteria for Adverse Events,version 4.0 [NCI-CTCAE v 4.0] [NCI 2009]):Grade(Gr)≥3 nonhematological toxicity,Gr4 thrombocytopenia lasting at least 5 days and/or complicated with bleeding,Gr≥3 febrile neutropenia(ntr),Gr4 ntr of >5 days' duration,increase(incr)of at least 1 gr from a preexisting Gr1 valvular insufficiency or any new Gr≥2 valvular toxicity,left ventricular(vtr) ejection fraction decrease of 10% in absolute value or 16% in relative value,incr in right vtr systolic pressure dysfunction from mild to moderate(mod) or from mod to severe,incr in left atrial or ventricular chamber size of ≥2 cm and ≥1cm respectively,any other life-threatening toxicity,significant morphologic on cardiac echocardiogram,any major ocular.
|
First Dose Up to 6 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of IMC-TR1
Time Frame: First Dose through Cycle 1 (6 Weeks)
|
The MTD was defined as the highest dose level at which ≤33% of participants experienced a DLT during Cycle 1.
|
First Dose through Cycle 1 (6 Weeks)
|
Maximum Tolerated Dose (MTD) of IMC-TR1 (1.25 mg/kg LY3022859 ) for Participants Receiving a Weight-Based Dose
Time Frame: First Dose through Cycle 1 (6 Weeks)
|
The MTD was defined as the highest dose level at which ≤33% of participants experienced a DLT during Cycle 1.
|
First Dose through Cycle 1 (6 Weeks)
|
Number of Dose-Limiting Toxicities (DLTs)
Time Frame: First Dose through Cycle 1 (6 Weeks)
|
First Dose through Cycle 1 (6 Weeks)
|
|
Immunogenicity - Development of Antibodies Against IMC-TR1
Time Frame: Cycle 1 - Day 1 and Day 29, Cycle 2 - Day 15, Cycle 3 and Each Consecutive Cycle - Day 1
|
Cycle 1 - Day 1 and Day 29, Cycle 2 - Day 15, Cycle 3 and Each Consecutive Cycle - Day 1
|
|
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (Antitumor Activity of IMC-TR1 as Monotherapy, Assessed Via Tumor Measurement by Response Evaluation Criteria in Solid Tumors, Version 1.1)
Time Frame: First Dose to Measured Progressive Disease (Up To 21.3 Weeks)
|
ORR is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1).
CR is a disappearance of all target and non-target lesions and normalization of tumor marker level.
PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of not-target lesions or appearance of new lesions.
Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
|
First Dose to Measured Progressive Disease (Up To 21.3 Weeks)
|
Pharmacokinetics (PK) - Area Under the Concentration-time Curve (AUC[0-tlast]) and AUCτ of IMC-TR1
Time Frame: Cycle (C) 1 Day (D) 1: 1, 2, 4, 8 hours (h); C1 D2: 24 h; C1 D3: 48 h; C1 D5: 96 h; C1 D8: 168 h; C1 D15: 336 h; C2 D15: 1, 2, 4, 8 h; C2 D16: 24 h; C2 D17: 48 h; C2 D19: 96 h; C2 D22: 168 h, C2 D29: 336 h
|
AUC (0-tlast) is area under the concentration versus time curve from the time zero to tlast. AUCτ is area under the concentration versus time curve during 1 dose interval (336 hours). |
Cycle (C) 1 Day (D) 1: 1, 2, 4, 8 hours (h); C1 D2: 24 h; C1 D3: 48 h; C1 D5: 96 h; C1 D8: 168 h; C1 D15: 336 h; C2 D15: 1, 2, 4, 8 h; C2 D16: 24 h; C2 D17: 48 h; C2 D19: 96 h; C2 D22: 168 h, C2 D29: 336 h
|
Pharmacokinetics - Maximum Concentration (Cmax) of IMC-TR1
Time Frame: Cycle (C) 1 Day (D) 1: 1, 2, 4, 8 hours (h); C1 D2: 24 h; C1 D3: 48 h; C1 D5: 96 h; C1 D8: 168 h; C1 D15: 336 h; C2 D15: 1, 2, 4, 8 h; C2 D16: 24 h; C2 D17: 48 h; C2 D19: 96 h; C2 D22: 168 h, C2 D29: 336 h
|
Cycle (C) 1 Day (D) 1: 1, 2, 4, 8 hours (h); C1 D2: 24 h; C1 D3: 48 h; C1 D5: 96 h; C1 D8: 168 h; C1 D15: 336 h; C2 D15: 1, 2, 4, 8 h; C2 D16: 24 h; C2 D17: 48 h; C2 D19: 96 h; C2 D22: 168 h, C2 D29: 336 h
|
|
Pharmacokinetics - Minimum Concentration (Cmin) of IMC-TR1
Time Frame: Cycle 2 Day 1: Prior to fourth infusion 0 hour (h)
|
Pharmacokinetics - Minimum concentration (Cmin) of IMC-TR1
|
Cycle 2 Day 1: Prior to fourth infusion 0 hour (h)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14549
- I5I-IE-JTCA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
Peking University First HospitalShengli Oilfield Hospital; The Second Affiliated Hospital of Baotou Medical...Enrolling by invitationRectal Neoplasms MalignantChina
-
Cancer Institute and Hospital, Chinese Academy...CompletedRectal Neoplasms MalignantChina
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
Clinical Trials on IMC-TR1
-
Eli Lilly and CompanyCompletedMalignant MelanomaUnited States
-
ImmuneOncia Therapeutics Inc.RecruitingAdvanced CancerKorea, Republic of
-
ImmuneOncia Therapeutics Inc.Not yet recruitingA Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
-
Innovative Med Concepts, LLCCompletedChronic Pain | Fibromyalgia | Myofascial PainUnited States
-
ImmuneOncia Therapeutics Inc.CompletedLymphoma | Solid TumorKorea, Republic of, United States
-
Eli Lilly and CompanyCompletedNeoplasms | Neoplasm MetastasisUnited States
-
Immunocore LtdRecruitingSelect Advanced Solid TumorsUnited States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland
-
CorAssist Cadiovascular Ltd.TerminatedHeart Failure With Normal Ejection Fraction
-
ImmuneOncia Therapeutics Inc.Active, not recruitingA Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeExtranodal NK/T-cell Lymphoma, Nasal Type | Extranodal NK/T-cell LymphomaKorea, Republic of
-
Virios Therapeutics, Inc.CompletedFibromyalgiaUnited States